The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) Trial
Open accessAbstract
Background—Although intravenous glycoprotein IIb/IIIa inhibitors are beneficial in patients with acute coronary syndromes, prolonged oral IIb/IIIa inhibition might provide an additional reduction in recurrent events. Methods and Results—Investigators at 888 hospitals in 29 countries enrolled 10 288 patients with acute coronary syndromes, which was defined as ischemic pain at rest within 72 hours of randomization, associated with positive cardiac markers, electrocardiographic changes, or prior cardiovascular disease. Patients received aspirin and were randomized to receive, for the duration of the trial, (1) 50 mg of orbofiban twice daily (50/50 group), (2) 50 mg of orbofiban twice daily for 30 days followed by 30 mg of orbofiban twice daily (50/30 group), or (3) a placebo. The primary composite end point was death, myocardial infarction, recurrent ischemia requiring rehospitalization, urgent revascularization, or stroke. The trial was terminated prematurely because of an unexpected increase in 30-day mortality in the 50/30 orbofiban group. Mortality through 10 months was 3.7% for the placebo group versus 5.1% in the 50/30 group (P=0.008) and 4.5% in the 50/50 group (P=0.11). There were no differences in the primary end point (22.9%, 23.1%, and 22.8%, for the placebo, 50/30, and 50/50 groups, respectively). Major or severe bleeding (but not intracranial hemorrhage) was higher with orbofiban; it occurred in 2.0%, 3.7% (P=0.0004), and 4.5% (P<0.0001) of patients, respectively. Exploratory subgroup analyses found that patients who underwent percutaneous coronary intervention had a lower mortality and a significant reduction in the composite end point (P=0.001) with orbofiban. Conclusions—Fixed-dose orbofiban failed to reduce major cardiovascular events and was associated with increased mortality in this broad population of patients with acute coronary syndromes; however, a benefit was observed among patients who underwent percutaneous coronary intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
(1998) · New England Journal of Medicine · doi:10.1056/nejm199808133390704 · Cited by 1,432
(1998) · New England Journal of Medicine · doi:10.1056/nejm199805213382102 · Cited by 1,321
Antman, E. M., McCabe, C. H., Gurfinkel, E. P., Turpie, A. G. G., Bernink, P. J. L. M., Salein, D., Bayes de Luna, A., Fox, K., Lablanche, J.-M., Radley, D., et al. (1999) · Circulation · doi:10.1161/01.cir.100.15.1593 · Cited by 1,052
Self-citationLigands “activate” integrin αIIbβ3 (platelet GPIIb-IIIa)
Du, X., Plow, E. F., Frelinger, A. L., O'Toole, T. E., Loftus, J. C., & Ginsberg, M. H. (1991) · Cell · doi:10.1016/0092-8674(91)90458-b · Cited by 486
Designs for group sequential tests
Fleming, T. R., Harrington, D. P., & O'Brien, P. C. (1984) · Controlled Clinical Trials · doi:10.1016/s0197-2456(84)80014-8 · Cited by 353
Kong, D. F., Califf, R. M., Miller, D. P., Moliterno, D. J., White, H. D., Harrington, R. A., Tcheng, J. E., Lincoff, A. M., Hasselblad, V., & Topol, E. J. (1998) · Circulation · doi:10.1161/01.cir.98.25.2829 · Cited by 348
Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial
Ault, K. A., Cannon, C. P., Mitchell, J., McCahan, J., Tracy, R. P., Novotny, W. F., Reimann, J. D., & Braunwald, E. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00635-4 · Cited by 249
Self-citation
Cited by
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citationBraunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
Self-citationCannon, C. P., Weintraub, W. S., Demopoulos, L. A., Vicari, R., Frey, M. J., Lakkis, N., Neumann, F.-J., Robertson, D. H., DeLucca, P. T., DiBattiste, P. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442501 · Cited by 2,103
Self-citationAnderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181940 · Cited by 1,853
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.013 · Cited by 1,510
Metadata
- Authors
- Cannon, C. P., McCabe, C. H., Wilcox, R. G., Langer, A., Caspi, A., Berink, P., Lopez-Sendon, J., Toman, J., Charlesworth, A., Anders, R. J., Alexander, J. C., Skene, A., & Braunwald, E.
- Venue
- Circulation
- Published
- 2000-07-11
- Volume
- 102
- Issue
- 2
- Pages
- 149-156
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2159258236
- Cited by
- 290
- References
- 16
- FWCI
- 27.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) Trial. https://app.cochat.ai/papers/10.1161/01.cir.102.2.149
- The paper
- Cannon, C. P., McCabe, C. H., Wilcox, R. G., Langer, A., Caspi, A., Berink, P., Lopez-Sendon, J., Toman, J., Charlesworth, A., Anders, R. J., Alexander, J. C., Skene, A., & Braunwald, E. (2000). Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) Trial. Circulation. https://doi.org/10.1161/01.cir.102.2.149
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.